tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Kaveri Pohlman, 25 are a BUY (78.13%), 7 are a HOLD (21.88%).
Analyst Kaveri Pohlman, currently employed at BTIG, carries an average stock price target met ratio of 34.62% that have a potential upside of 38.13% achieved within 143 days.
Kaveri Pohlman’s has documented 54 price targets and ratings displayed on 15 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on RAPT, RAPT Therapeutics at 20-Jan-2026.
Analyst best performing recommendations are on CMPI (CHECKMATE PHARMACEUTICALS).
The best stock recommendation documented was for CMPI (CHECKMATE PHARMACEUTICALS) at 3/30/2022. The price target of $9 was fulfilled within 20 days with a profit of $5.78 (179.5%) receiving and performance score of 89.75.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 16-Sep-2025
$10
$5.32 (113.68%)
$8
1 months 9 days ago
(04-Feb-2026)
12/18 (66.67%)
$4.33 (76.37%)
290
Buy Since 28-May-2024
$10
$5.32 (113.68%)
$5
1 months 21 days ago
(20-Jan-2026)
6/10 (60%)
$4.63 (86.22%)
205
Buy Since 15-May-2025
$10
$5.32 (113.68%)
$5
4 months 2 days ago
(11-Nov-2025)
2/3 (66.67%)
$5.9 (143.90%)
244
Hold Since 11-Jul-2022
1 years 2 months 6 days ago
(07-Jan-2025)
0/3 (0%)
$6.78 (160.66%)
Buy Since 08-Sep-2017
$8
$3.32 (70.94%)
$3
1 years 10 months 4 days ago
(09-May-2024)
4/9 (44.44%)
$5.96 (292.16%)
133
Which stock is Kaveri Pohlman is most bullish on?
Which stock is Kaveri Pohlman is most reserved on?
What Year was the first public recommendation made by Kaveri Pohlman?
